Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Bonalfa; Curatoderm; Psoraderm; Psoravit; TV 02; TV-02H

Latest Information Update: 23 Jun 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teijin Pharma
  • Developer Profex; Teijin Pharma
  • Class Anti-inflammatories; Antiallergics; Antipruritics; Antipsoriatics; Dihydroxycholecalciferols; Small molecules
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriasis

Most Recent Events

  • 17 Apr 2015 No recent reports on development identified - Preregistration for Plaque psoriasis in China (Topical)
  • 20 Sep 2010 Preregistration for Plaque psoriasis (20 µg/g dose) in China (Topical ointment)
  • 27 Jun 2006 Launched for Plaque psoriasis (20 µg/g dose) in Japan (Topical lotion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top